fbpx

Science

Study Title
Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality
Publication
Nature
Author(s)

Emmanuel Stamatakis, Matthew N. Ahmadi, Jason M. R. Gill, Cecilie Thøgersen-Ntoumani, Martin J. Gibala, Aiden Doherty & Mark Hamer

Abstract

Wearable devices can capture unexplored movement patterns such as
brief bursts of vigorous intermittent lifestyle physical activity (VILPA)
that is embedded into everyday life, rather than being done as leisure
time exercise. Here, we examined the association of VILPA with all-cause,
cardiovascular disease (CVD) and cancer mortality in 25,241 nonexercisers
(mean age 61.8 years, 14,178 women/11,063 men) in the UK Biobank. Over
an average follow-up of 6.9 years, during which 852 deaths occurred,
VILPA was inversely associated with all three of these outcomes in a
near-linear fashion. Compared with participants who engaged in no VILPA,
participants who engaged in VILPA at the sample median VILPA frequency
of 3 length-standardized bouts per day (lasting 1 or 2 min each) showed a
38%–40% reduction in all-cause and cancer mortality risk and a 48%–49%
reduction in CVD mortality risk. Moreover, the sample median VILPA
duration of 4.4 min per day was associated with a 26%–30% reduction in
all-cause and cancer mortality risk and a 32%–34% reduction in CVD mortality risk. We obtained similar results when repeating the above analyses for vigorous physical activity (VPA) in 62,344 UK Biobank participants who exercised (1,552 deaths, 35,290 women/27,054 men). These results indicate that small amounts of vigorous nonexercise physical activity are associated with substantially lower mortality. VILPA in nonexercisers appears to elicit similar efects to VPA in exercisers, suggesting that VILPA may be a suitable physical activity target, especially in people not able or willing to exercise.

Date
October 21, 2022
View study

Share This

Related Topics

Aerobic ExerciseExercise

Dr. Perlmutter is one of the leading lights in medicine today, illuminating the path for solving chronic illness

Mark Hyman, MD